Phase 3 Kidney Cancer Trial, Recruiting NCT04865939 Sponsor: University of Texas Southwestern Medical Center Condition: Kidney Cancer
Back to Kidney Cancer

Phase 3 Kidney Cancer Trial, Recruiting

NCT04865939
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with upper urinary tract cancer (in the kidney or ureter) confirmed by a biopsy, and you are scheduled for surgery to remove it with the goal of curing the disease
  • You are between 18 and 90 years old
  • Your doctor expects you to live for more than 1 year
  • If you are a woman who could become pregnant, you must agree to use reliable birth control (such as hormonal methods, barrier methods, or abstinence) before, during, and for 90 days after the study — and you must tell your doctor right away if you become pregnant or think you might be pregnant during the study
  • A woman is considered able to become pregnant for this study if she has not had her uterus or both ovaries removed, or has not gone through natural menopause for at least 12 months in a row
  • You are able to understand what the study involves and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You have been diagnosed with bladder cancer at the same time or in the past, unless you have been cancer-free for at least three years
  • You have the same type of cancer in both upper urinary tracts (both kidneys or ureters) at the same time — though a previous cancer on the other side is allowed if you have been cancer-free for more than three years
  • Your surgical plan includes removing the entire bladder
  • Your bladder is very small (holds less than 100 mL of fluid)
  • You have had a serious allergic reaction to gemcitabine or similar medicines that may be used in this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (214) 648-0389

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
29 November 2021
Est. completion
1 November 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

intravesical recurrence; intravesical recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov